Reviewer’s report
Title: 
Prevalence of Premature Ovarian Insufficiency and its determinants in
Iranian populations: Tehran Lipid and Glucose study
Version: 
1 
Date: 
19 Aug 2020
Reviewer's report:
Dear Respectable Editor 
Thank you to give me the opportunity to review the revised version of the
manuscript entitled (Prevalence of Premature Ovarian Insufficiency and its
determinants in Iranian populations: Tehran Lipid and Glucose study)
The study aimed to estimate the prevalence of POI and assessing the influential
factors.
The study found that the prevalence of POI (menopause age<40 years) and early
menopause (menopause age <45 years) were estimated 3.5% and 24.6%,
respectively. AFT model showed that in comparison to normal weight women,
time to menopause was decreased by -0.09 year (95%CI: -0.27, -0.01, P=0.023)
and -0.03 year (95%CI: -0.05, -0.02, P=0.000) in underweight and overweight
women, respectively. Moreover, time to natural menopause was increased by
0.12 year (95%CI: 0.07 to 0.17, p=0.000) in women used oral contraceptives
(OCPs) for >6 months.
In summary 
The results of the study were related to the prevalence of POI and early
menopause, the relation of weight and use of OPCs. The study aimed to estimate
the prevalence of POI and assessing the influential factors.
In the discussion (which should be conclusion) authors mentioned (In this study,
we found that 4.3% of participants experienced POI, 27.9% experienced early
menopause, situations that may lead to several public health concerns including
cardiovascular disease, osteoporosis, and breast and endometrial cancers). The
results of the authors did not include any data regarding the incidence or the
prevalence of cardiovascular diseases, osteoporosis, breast, and endometrial
cancers.
From where the authors get this conclusion. Did the conclusion of the authors
reflecting their results.
Major flaw 
The conclusion of the authors did not reflect their results.
The conclusion of the authors is not related to the aim of the study.
Regards 
Publons Reviewer Recognition
. Springer Nature can send verification of this
review directly to Publons (a subsidiary of Clarivate Analytics). If you would
like to take advantage of this service, please click on the “Yes” option below.
Your name, email address, title of the reviewed manuscript, name of the journal,
and date of your review submission (the “Review Data”) will then be transmitted
to Publons after the final decision on the manuscript has been made. If you have
already registered at Publons, they will notify you of the receipt of this review
and update your profile 
as per your settings and their policy. If you are not
registered with Publons, you will receive an email from them asking you to
register in order for them to be able to recognize your review on your new
profile page. Publons may use the Review Data to generate derivative metadata
for the benefit of Publons and you as a reviewer, carefully considering the
sensitivity of such information. For example, Publons may verify your record as
a reviewer by updating your profile published on its webservice if you have
registered for such service or help editors to identify candidate reviewers. Please
find the details of processing in Publons’ privacy policy
https://publons.com/about/terms
Yes
Declaration of competing interests
Please complete a declaration of competing interests, considering the following
questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
I declare no conflict of interest in relation to this article
Reviewer Publication Consent.
 I agree for my report to be made available
under an Open Access Creative Commons CC-BY License (
http://creativecommons.org/licenses/by/4.0
) if this manuscript is accepted for
publication. Any comments that I do not wish to be included in the published
report have been included as confidential comments to the editor, which will not
be published.
If you are not happy for us to publish this report, please contact the editorial
office before completing the review.
If you wish, you can include your name in your published report. Please note
you must decide whether to include your name at the start of the process and
confirm this decision whenever prompted. If you change your decision later, we
will not be able to publish your name.
I agree to the terms of the CC-BY 4.0 license; please publish my name with my
report.
Is the study design appropriate to answer the research question (including the use
of appropriate controls), and are the conclusions supported by the evidence
presented?
No
Are the methods sufficiently described to allow the study to be repeated?
No
Is the use of statistics and treatment of uncertainties appropriate?
No
Is the presentation of the work clear?
No
Are the images in this manuscript (including electrophoretic gels and blots) free
from apparent manipulation?
No